Breaking News

Trials & Filings in Brief: Oct. 17, 2013

By Gil Roth | October 17, 2013

AltheRx, AMAG, Discovery Labs, EMD Serono, Pfizer, Relypsa, Savara, Vertex

Phase II
Relypsa HKL treatment reduces serum potassium . . . read more

Savara receives CFFT grant for inhaled antibiotic . . . read more

Phase III
Huge R&D update from Vertex . . . read more

AltheRx gets patent for OAB combination . . . read more

AMAG PDUFA date delayed . . . read more

Discovery Labs files IND for Aerosurf . . . read more

EMD Serono Gonal-F injector pen approved . . . read more

Pfizer get expanded Prevnar 13 label in EU . . . read more
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials